Literature DB >> 22109716

Use of physiologically based pharmacokinetic models to evaluate the impact of intestinal glucuronide hydrolysis on the pharmacokinetics of aglycone.

Baojian Wu1.   

Abstract

Drug elimination via glucuronidation pathway is a complex process involving glucuronide excretion. Glucuronide excreted into the gut lumen either directly from the enterocytes or from the hepatobiliary route can be recovered back to the precursor (aglycone) through bacteria-mediated hydrolysis. As a result, the pharmacokinetics [e.g., plasma terminal half-life (T(1/2))] of aglycone might be altered. Here, impact of intestinal glucuronide hydrolysis on the pharmacokinetics of aglycone is evaluated using physiologically based pharmacokinetic (PBPK) models with liver and/or intestine as eliminating organs. It is found that compared with its absence, the presence of intestinal glucuronide hydrolysis leads to increases in the oral systemic bioavailability (F(sys)) of aglycone. The magnitude of fold increase is positively correlated with the level of metabolism, as metabolic clearance mainly contributes to recycled amount of glucuronide. Although F(sys) is independent of the glucuronide efflux in a traditional model and a segregated-flow model of the intestine, dependence of F(sys) on the glucuronide efflux can be observed in a segmental segregated-flow model of the intestine and whole-body PBPK models. Interestingly, when the ratio of apical versus basolateral efflux intrinsic clearances (of glucuronide) is fixed, their effects on the intestinal bioavailability and F(sys) cease to exist. In addition, glucuronide hydrolysis can lead to a significantly delayed elimination of the aglycone as evidenced by a prolonged (e.g., a 2.1-fold increase) T(1/2). Surprisingly, when a pharmacokinetic profile for aglycone is simulated with a flat terminal portion (a reflection of the experimental observations), changes in the aglycone bioavailabilities are limited (i.e., ≤ 1.3-fold). In conclusion, this study explores the possible role of intestinal glucuronide hydrolysis in the disposition of aglycone via simulations utilizing various PBPK models. The mechanistic observations should be helpful to better understand the complex glucuronidation in vivo.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22109716     DOI: 10.1002/jps.22827

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Absolute quantification of UGT1A1 in various tissues and cell lines using isotope label-free UPLC-MS/MS method determines its turnover number and correlates with its glucuronidation activities.

Authors:  Beibei Xu; Song Gao; Baojian Wu; Taijun Yin; Ming Hu
Journal:  J Pharm Biomed Anal       Date:  2013-08-29       Impact factor: 3.935

Review 2.  The human microbiome is a source of therapeutic drug targets.

Authors:  Bret D Wallace; Matthew R Redinbo
Journal:  Curr Opin Chem Biol       Date:  2013-05-13       Impact factor: 8.822

Review 3.  Understanding and modulating mammalian-microbial communication for improved human health.

Authors:  Sridhar Mani; Urs A Boelsterli; Matthew R Redinbo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-23       Impact factor: 13.820

4.  Challenges and Opportunities with Predicting in Vivo Phase II Metabolism via Glucuronidation from in Vitro Data.

Authors:  Shufan Ge; Yifan Tu; Ming Hu
Journal:  Curr Pharmacol Rep       Date:  2016-11-08

5.  A UPLC-MS/MS Method for Simultaneous Determination of Free and Total Forms of a Phenolic Acid and Two Flavonoids in Rat Plasma and Its Application to Comparative Pharmacokinetic Studies of Polygonum capitatum Extract in Rats.

Authors:  Yong Huang; Hui-Yuan Sun; Xiao-Li Qin; Yong-Jun Li; Shang-Gao Liao; Zi-Peng Gong; Yuan Lu; Yong-Lin Wang; Ai-Min Wang; Yan-Yu Lan; Lin Zheng
Journal:  Molecules       Date:  2017-02-25       Impact factor: 4.411

Review 6.  Bringing microbiome-drug interaction research into the clinic.

Authors:  Leah Guthrie; Libusha Kelly
Journal:  EBioMedicine       Date:  2019-05-28       Impact factor: 8.143

Review 7.  The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug-Drug Interactions.

Authors:  K Sandy Pang; H Benson Peng; Keumhan Noh
Journal:  Pharmaceutics       Date:  2020-04-01       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.